Lupin Q4 Results 2025 Today: Analysts Expect Strong YoY Growth on Robust Sales, Most Brokerages Rate ‘Buy’

Global pharma major Lupin Limited (BSE: 500257 | NSE: LUPIN) is set to report its financial performance for the quarter ending March 31, 2025. The unaudited results will be taken on record by the Board of Directors at a meeting today.

Top Market Brokerages anticipate a strong year-on-year performance from Lupin this quarter, though sequential growth may be muted. The company is expected to post solid sales in major markets, supported by reduced price erosion and the impact of recent key product launches.

Lupin Q4 Results 2025 Preview: Strong Growth Expected, New Medicines to Boost Sales

Pharma major Lupin is expected to post a strong performance for the fourth quarter of financial year 2024-25 (Q4 FY25), with solid growth in revenue and profit compared to the same period last year. According to market analysts, the company is likely to see a revenue increase of around 11.6% to 14% year-on-year, while earnings before interest, taxes, depreciation, and amortization (EBITDA) could grow by 32% to 37.4%, and net profit (PAT) may rise by 23% to 33.4%.

Buy, Hold or Sell Lupin Stock? Get Market Analysts' Recommendations

Out of the total analyst recommendations, 22 have rated Lupin as a 'Buy', 10 as 'Hold', and 5 have recommended 'Sell', indicating overall positive sentiment toward the stock.

Brokerage firms like Nomura, Choice Broking, Axis Securities, and HDFC Securities are optimistic about Lupin's performance this quarter. Nomura expects a pickup in US sales due to the launch of high-value products. Choice predicts recovery in the Indian market and improved profit margins thanks to lower raw material costs. Axis points to gains from both existing and newly launched US generics.

Key Drivers of Lupin's Growth

A major factor behind this expected growth is Lupin's strong performance in the US market, which is one of its largest revenue contributors. New generic drug launches, including Tolvaptan and gXarelto, are seen as key to boosting US sales. Additionally, the company's already successful products such as gSpiriva, gMyrbetriq, gSupreb, and gPrezista are expected to continue showing good traction.

In India, Lupin's growth is expected to be driven by its chronic therapy segment, which includes long-term treatments for conditions like diabetes, heart disease, and asthma. Analysts at HDFC Securities (HSIE) believe this will play an important role in boosting the company's overall performance.

However, some caution remains. The company's increased spending on research and development (R&D) could limit the growth in its operating profit margins, despite the higher sales.

Lupin Earnings Call 2025 Today: What to Expect?

Overall, Lupin is expected to deliver a strong year-on-year (YoY) performance, even though growth may not be as high compared to the previous quarter. Analysts will be closely watching the company's Q4 earnings announcement for updates on new drug launches, margin trends, and performance across key markets like the US and India.
Lupin's results will provide important signals about the strength of its pipeline and whether the recent product launches are translating into consistent revenue gains.

Disclaimer:

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.